AbbVie Inc vs Corning Incorporated — how do they compare? AbbVie Inc trades at $250.35 (market cap $438.19B), while Corning Incorporated trades at $161.37 (market cap $135.89B). The key difference: AbbVie Inc is far larger — about 3.2× Corning Incorporated's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | GLW | |
|---|---|---|
Market Cap | $438.19B | $135.89B |
Sector | Health | Technology |
52-Week High | $263.58 | $255.79 |
52-Week Low | $197.38 | $64.52 |
Enterprise Value | $502.45B | $142.77B |
Dividend Yield | 2.79% | 0.71% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
GLW trades at $165.69, up 5.41% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $15.63B in 2025, with net income surging to $1.60B. The stock is supported by AI-driven optical demand and analyst optimism, though valuation multiples like a P/E of 76.35 appear elevated. Recent news highlights partnerships with major tech firms and a strategic focus on photonics expansion.
The outlook for GLW is positive, driven by AI infrastructure growth and a $10B photonics goal, but risks include high valuation sensitivity and execution challenges. Analysts project a 16.6% upside to the $193.33 consensus target, with 57% recommending buy. Investors should weigh robust fundamentals against premium pricing and competitive pressures in the semiconductor supply chain.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →